Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.46 USD
-0.03 (-5.33%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.45 -0.01 (-1.51%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Sangamo Therapeutics, Inc.'s return on equity, or ROE, is -284.27% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that SGMO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
SGMO 0.46 -0.03(-5.33%)
Will SGMO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for SGMO
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ...
Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript
Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Sangamo Therapeutics GAAP EPS of -$0.08 misses by $0.04, revenue of $18.3M misses by $13.38M